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Abstract
Background: The objective of this review was to investigate trends in clinical
trial design, specifically, the primary outcomes used, interpretation of results, and
the magnitude of the benefits described in phase III controlled clinical trials in
the first-line treatment of patients with advanced non-small cell lung cancer
(NSCLC).
Methods: Seventy-six trials published between 2000 and 2012 were selected from
a total of 122 identified in a structured search.
Results: Overall survival (OS) was evaluated as the primary study endpoint in
50 (65.8%) trials, followed by progression-free survival (PFS) in 15 (19.7%), and
other variables, such as toxicity, quality of life (QoL), and response rate in
11 (14.5%). Ten (66.7%) out of 15 clinical trials using PFS as the primary end-
point were published between 2010 and 2012. Median overall survival (mOS)
was 9.90 months (interquartile range: 3.5) with an increase of 0.384 months per
year of publication (P < 0.001). A statistically significant improvement in mOS
was obtained in only 13 (18.8%) trials. A total of 41 (53.9%) studies concluded
that the result was positive. Of these, only 16 (39.1%) showed a statistically sig-
nificant benefit in OS. QoL was assessed in 46 trials (60.5%) and of these,
10 (21.7%) reported significant improvements.
Conclusions: These findings raise important questions about how clinical bene-
fits are measured in clinical trials in advanced NSCLC. Appropriate clinically rel-
evant outcome variables should be established and validated, and post-marketing
studies should be requested by regulatory authorities to ensure meaningful clini-
cal benefits in OS and QoL.
Introduction
Advanced non-small cell lung cancer (NSCLC) is the lead-
ing cause of cancer-related death worldwide.1 Conse-
quently, it has been the subject of extensive investigation
over several decades, showing the growing interest of the
oncology community and the pharmaceutical industry in
this clinical entity.2 However, despite great efforts in
research, the clinical benefit of new therapies has been
modest,3 and treatment of lung cancer patients remains
one of the greatest challenges in oncology.
Although the goal of research in cancer therapy is to
improve the quantity and quality of life,4,5 a growing num-
ber of questions have been raised with respect to the mag-
nitude of the benefits shown in clinical trials in oncology.
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One of the difficulties in evaluating the clinical benefit of
new cancer drugs is the numerous outcome measures used
in clinical trials, and there is emerging concern regarding
the design of such trials in oncology resulting from the
increasing trend in measuring effectiveness through surro-
gate variables (i.e. progression-free survival [PFS], time to
progression [TTP], etc.).6–9 The evidence supporting the
use of surrogate endpoints in oncology is inconsistent6,8,10,11
and, moreover, the reliability of the correlation between
surrogate measures and meaningful outcomes like overall
survival (OS) or quality of life (QoL) has not always been
validated or is uncertain.12,13 Although OS is still accepted
as the gold standard for efficacy endpoints in lung cancer
studies,14 its use as the primary endpoint appears to be
declining in clinical trials investigating advanced NSCLC.
Furthermore, an increasing trend toward positive interpre-
tations of the results of clinical trials in oncology despite
modest or questionable clinical benefits has also been
reported.15
The aim of the study was to investigate trends in clinical
trial design with respect to the primary outcomes used, the
interpretation of the results, and the magnitude of the ben-
efits described from first-line treatment of patients with
advanced NSCLC in studies published between 2000
and 2012.
Methods
Search strategy and study selection
criteria
A structured search was conducted for randomized phase
III clinical trials (RCTs) in the first-line treatment of
patients with advanced NSCLC published between 2000
and 2012. MEDLINE (accessed via PubMed and Ovid SP);
Embase (Ovid SP); the Cochrane Central Register of Con-
trolled Trials, Cochrane Library (CENTRAL); Evidence-
Cancer (via NHS); and TRIP (via BV-SSPA) were searched
using the following terms: lung cancer, non-small,
advanced, non-surgical, treatment, controlled clinical trial,
and phase III. To be included in the study, trials had to
have at least two comparative arms of systemic chemother-
apy or molecular-targeted agents in patients with advanced
NSCLC. In trials with two or more experimental arms, the
arm selected for evaluation in this review was the one that
obtained the highest OS or PFS, depending on the primary
outcome endpoint of the trial. Only RCTs published in
journals were selected. Exclusion criteria were: RCTs study-
ing only non-advanced disease or any stage of small-cell
lung cancer other than advanced stage; surgical or radio-
therapy intervention studies or cancer screening and pre-
vention studies; meta-analyses or reviews reporting data
from multiple RCTs; preliminary studies for which
subsequent phase III studies were available; retrospective
series; congress abstracts; and studies in a language other
than English.
Data extraction, analysis, and
management
Two investigators independently extracted data from each
selected publication using a specifically designed form to
record the following information: publication year, primary
and secondary endpoints, assessment of QoL, median over-
all survival (mOS, months), median progression-free sur-
vival (mPFS, months) per arm, and any statistically
significant differences observed between treatment arms.
We also recorded the authors’ conclusions on the experi-
mental arm and summarized them as a positive result, neg-
ative result, or similar result for experimental versus
control arms.
Results
Characteristics of selected trials
As shown in Figure 1, of the 122 trials retrieved for further
evaluation, 46 were excluded after applying the study eligi-
bility criteria. The 76 trials finally selected for this review
(a list of the 76 clinical trials is given as online supporting
information) involved a total of 40 765 patients with
advanced NSCLC randomly assigned to 152 treatment
arms. The characteristics of these 76 selected trials are
summarized in Table 1.
 Potentially eligible trials identified as a result of the search (n = 312) 
Trials retrieved for more detailed evaluation (n = 122) 
Trials excluded after reading abstract (n = 190) 
Reasons: nonrandomized trial, retrospective 
analysis, cost-effectiveness study, indirect 
comparison, sub-study, other treatment 
modalities. 
Trials included in our study (n = 76) 
Trials excluded after reading full text (n = 46)  
Reasons: not first-line treatment (n =15), 
radiotherapy regimens (n = 8), randomized Phase 
II trial (n = 7), survival data not reported (n = 4), 
only immunotherapy regimens studied (n = 3), 
subgroup analyses (n = 4), preliminary studies 
(n = 2), review article (n = 1), and prematurely 
halted (n = 2). 
Figure 1 Flowchart depicting the trial selection process for the review.
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First and secondary endpoints in
randomized controlled trials of non-small
cell lung cancer
OS was used as a primary study endpoint in 50 (65.8%) of
the 76 selected clinical trials for the first-line treatment of
advanced NSCLC published between 2000 and 2012, fol-
lowed by PFS in 15 trials (19.7%), and other variables, such
as toxicity, QoL, and response rate, in 11 (14.5%). It should
be noted that 10 of the 15 clinical trials using PFS as the
primary endpoint were published between 2010 and 2012.
OS data were available in 69 (90.8%) trials, and of these,
only 13 (18.8%) reported a statistically significant OS bene-
fit in the experimental arm. The remaining 56 (81.2%) tri-
als did not demonstrate a statistically significant increase
in OS compared to alternative treatments. We also exam-
ined total gains in OS obtained over the study period: mOS
for the 76 trials was 9.90 months (interquartile range
[IQR] 3.5), with a total mean improvement in OS of
0.384 months per year (P < 0.001).
PFS data were available in 67 (88.2%) of the 76 trials,
and a significant difference between arms was reported in
26 (38.8%). The mPFS reported in trials during the study
period was 4.90 months (IQR 1.9).
A total of 41 (53.9%) studies were considered to have
concluded that the results were positive, based on the
authors’ recommendations for the treatment to be adopted
in clinical practice or in further studies. These positive con-
clusions were supported by a statistically significant result
in the primary study endpoint in only 25 (61%) clinical tri-
als. Of these, OS was the primary outcome in 11; surrogate
measures, such as PFS, were the primary endpoint in a fur-
ther 11 clinical trials; and finally, toxicity, QoL, and
response rate were the primary endpoints in the three
remaining clinical trials that were able to show statistically
significant differences in the primary study endpoint.
In 16 (39%) of the 41 clinical trials that concluded that a
positive result had been obtained in the experimental arm,
no statistically significant differences in the primary study
endpoint were shown, and the results were supported by
secondary measures, such as lower toxicity (8/16),
improvement in response rate (1/16), significant improve-
ment in QoL (2/16), statistically significant improvement
in PFS (3/16), and statistically significant improvement in
OS (2/16).
QoL was evaluated in 46 (60.5%) trials and a statistically
significant improvement in this endpoint was found in
10 (21.7%). A total of 10 different measurement instru-
ments were identified. The specific Functional Assessment
of Cancer Therapy Lung Cancer questionnaire (FACT-
LCS5) was used in 23 (50%) trials, the European Organiza-
tion for Research and Treatment of Cancer Quality of Life
questionnaire C30 (EORTC QLQ C-30) in 20 (43.5%), and
the specific EORTC lung cancer questionnaire (EORTC
QLQ LC-13) in 17 (37.0%).
Discussion
In recent years, there has been debate over the increasing
use of surrogate variables, such as PFS, instead of the OS
primary endpoint in the design of clinical trials in oncol-
ogy.6,8 In our study, 65.8% (50/76) of the trials published
between 2000 and 2012 used OS as the main variable, fol-
lowed by PFS in 19.7% (15/76), and other variables in
14.5% (11/76). It should be highlighted that 66% of the
RCTs that included PFS as the primary endpoint were
published from 2010 to 2012, the last two years of our
12-year study period. Our work therefore confirms the
increasing trend toward the use of PFS as the primary end-
point in RCTs in advanced NSCLC and the declining use
of OS or QoL.
Some authors believe this trend to be the result of an
increasing willingness of regulatory authorities to accept
the use of surrogate variables as primary study endpoints,15
the common use of crossover trial designs and subsequent
Table 1 Characteristics of the 76 selected clinical trials
Variable N (%)
Publication year
2000 3 (3.9)
2001 5 (6.6)
2002 7 (9.2)
2003 7 (9.2)
2004 7 (9.2)
2005 7 (9.2)
2006 7 (9.2)
2007 6 (7.9)
2008 5 (6.6)
2009 4 (5.3)
2010 7 (9.2)
2011 5 (5.3)
2012 7 (9.2)
No. of randomized patients
< 500 46 (60.5)
501–1000 17 (22.4)
> 1000 13 (17.1)
Median (range) 432 (126–1725)
Primary endpoint
OS 50 (65.79)
PFS 15 (19.74)
Other (RR, QoL, toxicity) 11 (14.47)
Follow-up median (range), months 17.6 (2.7–60)
Not recorded 29
Authors’ conclusion
Positive result 41 (53.9)
Negative result 25 (32.9)
Similar result 10 (13.2)
OS, overall survival; PFS, progression-free survival; RR, response rate;
QoL, quality of life.
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lines of treatment that may dilute the overall survival bene-
fit, or longer follow-up times in trials using OS as the pri-
mary endpoint.11 The Food and Drug Administration
recently accepted the use of PFS as a primary endpoint in
trials studying the treatment of advanced NSCLC but with
reservations regarding the accuracy, reproducibility, and
clinical relevance of this surrogate variable,14 and concludes
that OS is still the standard clinical benefit outcome vari-
able that should be used to establish the efficacy of a ther-
apy in patients with advanced NSCLC. The fact is that the
advantages gained from faster drug approval and patient
access to new agents are questionable if they rely on results
of studies based on surrogate variables that do not translate
into benefits in terms of OS or QoL.
Many of the surrogate variables used as primary out-
come measures in clinical trials are poorly correlated with
survival or QoL, or the correlation has not been
tested.12,16,17 Moreover, most regulatory approvals based on
these surrogate variables do not usually require post-
marketing studies to be conducted to confirm or validate
effectiveness and safety results that allow translating PFS
benefit into meaningful clinical benefit for patients, that is,
OS or QoL.
There is currently an interesting and necessary debate
regarding when it should be demonstrated that a cancer
drug leads to an improvement in OS or QoL. Some argue
that this should occur before market authorization while
others believe that in some indications, such as advanced
NSCLC, a drug could receive provisional approval based
on surrogate endpoints, and its benefit on OS or QoL
should be demonstrated in post-marketing trials. However,
according to two recent studies, this rarely happens.18,19
One of these studies that evaluated evidence of the OS or
QoL benefits of cancer drugs approved by the European
Medicines Agency stated that results reported in the post-
marketing period confirming a positive impact on survival
and QoL are very rare for new cancer drugs that have been
approved based on a benefit in surrogate variables.19
Our findings suggest that positive conclusions describing
a meaningful clinical benefit in patient outcome are
extremely common, even when no statistically significant
differences in the primary study endpoint are obtained.
Similarly, studies frequently reach a positive conclusion
without having demonstrated a positive impact on the two
most important outcomes for patients, OS and QoL. In our
study, of the 41 clinical trials with positive conclusions,
only 16 were based on a statistically significant OS gain.
A total of 41 (53.9%) clinical trials concluded their
results in the experimental arm were positive, a figure simi-
lar to that reported by Sacher et al. in their review of phase
III clinical trials in advanced NSCLC.15 They found posi-
tive conclusions in only 31% of clinical trials conducted
between 1980 and 1990, compared to 53% in clinical trials
carried out between 2001 and 2010. These results confirm
the increasing trend toward positive interpretations of the
results of clinical trials in NSCLC, even when no statisti-
cally significant differences in the main variable were
shown. In our study, the percentage of trials showing a sta-
tistically significant improvement in the primary endpoint
was 32.8%, a result very similar to the 31% described by
Sacher et al. for the 2001–2010 study period. In this regard,
Sacher et al. pointed out that the percentage of trials
reporting a statistically significant benefit in the primary
endpoint had not changed over time (29% in 1980–1990
and 31% in 2001–2010). However, the percentage of trials
reporting a positive result despite not showing a statisti-
cally significant benefit in their primary outcome measure
had clearly increased over time (30% of positive trials in
1981–1990 vs. 24% in 1991–2000 vs. 53% in 2001–2010;
P = 0.001).15
QoL in cancer patients has been found to be a strong
predictor of survival and toxicity. However, this outcome
variable was evaluated in only 60.5% of clinical trials
included in the present study. Moreover, only 21.7% of
these trials reported a significant improvement in QoL.
This result is better than that reported by Tanvetyanon
et al. in their systematic review of QoL associated with che-
motherapy for NSCLC, where only 7.1% of trials analyzed
demonstrated a significant difference in QoL.20 Overall,
QoL results have shown modest improvement and further
research on this outcome in NSCLC patients, using more
uniform methodologies, is necessary.
There are some limitations to this study. Firstly, publica-
tion bias is one of the main limitations of review studies and
along with this, selection bias is one of the main criticisms
of reviews and meta-analyses. However, we minimized this
bias by designing and applying a structured and well-defined
search strategy. In addition, five different databases were
searched and two researchers independently selected the
studies. Secondly, it was not always possible to obtain all of
the data required to evaluate the methodology and outcomes
of the studies. In addition, PFS and TTP were considered as
surrogate endpoints of survival and as interchangeable vari-
ables, in common with other authors.10,13,21 Thirdly, the time
period studied should be extended in order to include clini-
cal trials investigating immunotherapy regimens. This will
be taken into account in future research.
The present review shows that most of the clinical trials
in advanced NSCLC published between 2000 and 2012 did
not demonstrate a statistically significant improvement in
OS or QoL over alternative treatments.
There is a lack of studies examining the design of clini-
cal trials in advanced NSCLC treatment. Our findings raise
important questions about how clinical benefits are mea-
sured in clinical trials in advanced NSCLC. Appropriate
clinically relevant outcome variables should be established
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and validated, and post-marketing studies in OS and QoL
should be requested by regulatory authorities to ensure
meaningful clinical benefits.
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